Company & Sponsor Intelligence

Medical University of Lodz

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting2

Completed0

Countries1

Therapeutic footprint

adhdalzheimersschizophrenia

Indexed studies

NCT05957055Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes
adhd · PolandPHASE2

NCT06850597Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
alzheimers · PolandPHASE2

NCT02210962Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia
schizophrenia · PolandPHASE4

Intelligence layer updated: 2026-10-15 06:14:04.252491+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →